A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.

ABSTRACT:

Background

Clinical benefit from checkpoint inhibitors has been associated in a tumor-agnostic manner with two main tumor traits. The first is tumor antigenicity, which is typically measured by tumor mutation burden, microsatellite instability (MSI), or Mismatch Repair Deficiency using gene sequence platforms and/or immunohistochemistry. The second is the presence of a pre-existing adaptive immune response, typically measured by immunohistochemistry (e.g. single analyte PD-L1 expression) and/or gene expression signatures (e.g. tumor "inflamed" phenotype). These two traits have been shown to provide independent predictive information. Here we investigated the potential of using gene expression to predict tumor MSI, thus enabling the measurement of both tumor antigenicity and the lev

SUBMITTER: Danaher P 

PROVIDER: S-EPMC6341623 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature